Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15044829 | 0.76 | PARL (0.33) | PARL | |
| SCHEMBL9349458 | 0.74 | PARL (0.32) | PARL | |
| SCHEMBL8348981 | 0.69 | PARL (0.39) | PARLALOX12 | |
| SCHEMBL182701 | 0.69 | PARL (0.39) | PARLALOX12 | |
| SCHEMBL317848 | 0.67 | MGLL (0.35) | — | |
| SCHEMBL784740 | 0.65 | — | — | |
| SCHEMBL16015094 | 0.65 | — | — | |
| SCHEMBL21827564 | 0.65 | — | — | |
| SCHEMBL9656768 | 0.65 | — | — | |
| SCHEMBL7156883 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371662-A1 | METHOD FOR ANALYZING REACTIVE LOW-MOLECULAR-WEIGHT COMPOUND CONTAINED IN POLYOXYETHYLENE DERIVATIVE | NOF Corporation (JP) | 2024-05-22 | — | — | EP | claimed |
| US-11945882-B2 | Method for producing antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-02 | — | — | US | claimed |
| WO-2023198922-A1 | METHOD FOR PRODUCING A HYDROGEL COMPRISING A CROSS-LINKED SILYLATED POLYSACCHARIDE | Teoxane SA (CH) | 2023-10-19 | — | — | WO | claimed |
| WO-2023198917-A1 | HYDROGELS FOR SOFT TISSUE FILLING | Teoxane SA (CH) | 2023-10-19 | — | — | WO | claimed |
| US-20230330305-A1 | HYDROGEL COMPRISING A CROSS-LINKED AND SILYLATED POLYSACCHARIDE AND PROCESS FOR OBTAINING SAME | Teoxane SA (CH) | 2023-10-19 | — | — | US | claimed |
| WO-2023198920-A1 | METHOD FOR PRODUCING A HYDROGEL | Teoxane SA (CH) | 2023-10-19 | — | — | WO | claimed |
| WO-2023198913-A1 | HYDROGELS FOR SOFT TISSUE FILLING | Teoxane SA (CH) | 2023-10-19 | — | — | WO | claimed |
| WO-2023198915-A1 | HYDROGELS FOR FILLING SOFT TISSUES | Teoxane SA (CH) | 2023-10-19 | — | — | WO | claimed |
| WO-2023145936-A1 | STYRENIC POLYMER PRODUCTION METHOD | 富士フイルム和光純薬株式会社 | 2023-08-03 | — | — | WO | claimed |
| EP-4210655-A1 | HYDROGEL COMPRISING A CROSSLINKED AND SILYLATED POLYSACCHARIDE AND PROCESS FOR OBTAINING SAME | Teoxane SA (CH) | 2023-07-19 | — | — | EP | claimed |
| WO-1994009128-A1 | THERAPEUTIC TREATMENT FOR INHIBITING VASCULAR RESTENOSIS | MALLINCKRODT MEDICAL, INC. (US) | 1994-04-28 | — | — | WO | claimed |
| EP-0199804-B1 | LUMINESCENT METAL CHELATE LABELS AND MEANS FOR DETECTION | IGEN INC (US) | 1994-04-06 | — | — | EP | claimed |
| EP-0401302-A4 | — | — | 1994-03-30 | — | — | EP | claimed |
| EP-0263657-B1 | POLYSUBSTITUTED ARYL ACRIDINIUM ESTERS | Ciba Corning Diagnostics Corp. (US) | 1992-05-13 | — | — | EP | claimed |
| EP-0401302-A1 | METHOD OF PREPARING A METAL-RADIONUCLIDE-LABELLED PROTEIN. | MALLINCKRODT INC (US) | 1990-12-12 | — | — | EP | claimed |
| US-4927769-A | OXIDIZING AN ACRIDINIUM ESTER IN THE PRESENCE OF A CATIONIC SURFACTANT, NONIONIC SURFACTANT OR SULFATED PRIMARY ALCOHOL | CIBA CORNING DIAGNOSTICS CORP. (US) | 1990-05-22 | — | — | US | claimed |
| WO-1989007456-A1 | METHOD OF PREPARING A METAL-RADIONUCLIDE-LABELLED PROTEIN | MALLINCKRODT, INC. (US) | 1989-08-24 | — | — | WO | claimed |
| WO-1989006231-A1 | ASSAYS UTILIZING IMPROVED CHEMILUMINESCENT ESTERS, THIOESTERS AND AMIDES | LONDON DIAGNOSTICS, INC. (US) | 1989-07-13 | — | — | WO | claimed |
| EP-0322926-A2 | Assays utilizing improved chemiluminescent esters, thioesters and amides | LONDON DIAGNOSTICS, INC. (US) | 1989-07-05 | — | — | EP | claimed |
| EP-0273115-A2 | Chemiluminescent acridinium and phenanthridinium salts | ABBOTT LABORATORIES (US) | 1988-07-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945882-B2 | Method for producing antibody-drug conjugate | UGT1A9, ALB, MRPL21 | PARL 4624/4885ALOX12 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.